Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT known ✓ | P43490 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30556139 | 1.00 | EPHX2 (0.65) | EPHX2CYP2C9CYP2C19RAB9AKMT2A | |
| SCHEMBL31110600 | 0.95 | EPHX2 (0.59) | EPHX2CYP2C9CYP2C19RAB9AKMT2A | |
| SCHEMBL31110594 | 0.95 | EPHX2 (0.59) | EPHX2CYP2C9CYP2C19RAB9AKMT2A | |
| SCHEMBL31259755 | 0.88 | EPHX2 (0.67) | EPHX2CYP2C9CYP2C19RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL25330075 | 0.88 | EPHX2 (0.67) | EPHX2CYP2C9CYP2C19RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL25330240 | 0.87 | EPHX2 (0.73) | EPHX2CYP2C9CYP2C19RAB9AKMT2A | |
| SCHEMBL31110586 | 0.86 | EPHX2 (0.59) | EPHX2CYP2C9CYP2C19RAB9AKMT2A | |
| SCHEMBL31110581 | 0.85 | EPHX2 (0.58) | EPHX2CYP2C9CYP2C19RAB9AKMT2A | |
| SCHEMBL31110598 | 0.84 | EPHX2 (0.62) | EPHX2CYP2C9CYP2C19RAB9AKMT2A | |
| SCHEMBL25948339 | 0.81 | EPHX2 (0.85) | EPHX2CYP2C9CYP2C19RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472948-A2 | NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF | New Frontier Bio, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20230242558-A1 | NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF | New Frontier Bio, Inc. | 2023-08-03 | — | — | US | disclosed |
| WO-2023147161-A2 | NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF | New Frontier Bio, Inc. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242558-A1 | NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF | NAMPT, NNT, NAPRT | NAMPT 1/4885EPHX2 2935/4885CYP2C9 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.